Quidelortho Corporation · NASDAQ:QDEL
Quidelortho — Q4 2022 Earnings Presentation
20 slides from Quidelortho's earnings presentation, Feb 15, 2023
Slide 1: QuidelOrtho Financial Results 4Q & FY 2022
February 15, 2023 QuidelOrtho Financial Results 4Q & FY 2022
Slide 2: Forward-Looking Statements
© 2023. All Rights Reserved. 2 Forward-Looking Statements Forward-Looking Statements: This presentation of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these
Slide 3: Supplemental Combined Financial Measures and Non-GAAP Financial Measures
© 2023. All Rights Reserved. 3 Supplemental Combined Financial Measures and Non-GAAP Financial Measures Supplemental Combined Financial Measures: This presentation contains unaudited supplemental combined financial information (“Supplemental Combined Information”) that gives effect to the Combinatio
Slide 4: 4Q 2022 Highlights
© 2023. All Rights Reserved. 4 4Q 2022 Adjusted 1 Total Revenue Adjusted EPS Highlights EBITDA $867M $1.76 2 $245M 22 1 1 (23%) y/y (66)% y/y • Strong finish to the year with a 28.3% Margin 1 great Q4 that exceeded our expectations • Supplemental combined revenue Business Unit Geography Category gro
Slide 5: Strategic Priorities
© 2023. All Rights Reserved. 5 Strategic Priorities Integration and Culture Unite the people, processes and products of QuidelOrtho to accelerate innovation, expand commercial reach and improve patient outcomes across the healthcare continuum within a culture of speed, happiness and engagement. Prod
Slide 6: Financial Results
Financial Results @® QuidelOrtho”
Slide 7: 4Q 2022 Supplemental Combined Revenue Results
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 7 1 4Q 2022 Supplemental Combined Revenue Results Other QuickVue Transfusion 13% Instruments 14% Medicine 4% MDx China 19% 7% 2% Labs 36% EMEA 9% Recurring 82% North America POC 71% 43% Revenue Revenue Revenue by Business Unit
Slide 8: Supplemental Combined Operating Results Summary
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 8 1 Supplemental Combined Operating Results Summary Solid Results Demonstrate Resiliency of Our Business Model Fiscal Quarter Ended 4Q 2022 4Q22 2 4Q21 1 Highlights Total Revenue $866.5 $1,157.9 Constant Currency Growth (23.4%)
Slide 9: Strong Cash Flow and Balance Sheet Provide Flexibility and Stability
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 9 Strong Cash Flow and Balance Sheet Provide Flexibility and Stability 1 1 4Q 2022 Cash Flow 4Q 2022 Balance Sheet $169M 2 $366M Operating Cash Flow Cash & ~1.5x Marketable Securities $135M Net Debt to Adjusted EBITDA 4 Recurri
Slide 10: FY 2023 Guidance
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 10 1 FY 2023 Guidance $2.21 – 2.25 Billion $2.8 – 3.1 Billion (+4% – 6% constant currency) (Down 30% – 22% constant currency) Total Revenue Total Revenue, Ex-Respiratory $610 – 875 Million ~ Neutral Currency Translation Headwin
Slide 11: Summary
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 11 Summary • Strong finish to the year with a great fourth quarter that exceeded our expectations • FY 2023 guidance is in line with the three year outlook that we gave at our investor day • Confident in our strategic prioritie
Slide 12: Appendix
@® QuidelOrtho
Slide 13: 4Q 2022 Non-GAAP Reconciliation
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 13 4Q 2022 Non-GAAP Reconciliation Selling, Research and Operating Operating Interest Other Provision for Gross profit marketing and Net income development income income margin expense, net expense, net income taxes adiministra
Slide 14: FY 2022 Non-GAAP Reconciliation
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 14 FY 2022 Non-GAAP Reconciliation Selling, Research and Operating Operating Interest Other Provision for Gross profit marketing and Net income development income income margin expense, net expense, net income taxes adiministra
Slide 15: 4Q 2021 Non-GAAP Reconciliation
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 15 4Q 2021 Non-GAAP Reconciliation Selling, Research and Operating Operating Interest Other Provision for Gross profit marketing and Net income development income income margin expense, net expense, net income taxes adiministra
Slide 16: FY 2021 Non-GAAP Reconciliation
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 16 FY 2021 Non-GAAP Reconciliation Selling, Research and Operating Operating Interest Other Provision for Gross profit marketing and Net income development income income margin expense, net expense, net income taxes adiministra
Slide 17: QTD Pro Forma Revenue by Region, Business Unit, and Category
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 17 QTD Pro Forma Revenue by Region, Business Unit, and Category Three Months Ended (a) Currency (a) Less: COVID-19 Constant Currency Segment revenue January 1, 2023 January 2, 2022 Percent Change Constant Currency Impact revenu
Slide 18: YTD Pro Forma Revenue by Region, Business Unit, and Category
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 18 YTD Pro Forma Revenue by Region, Business Unit, and Category Fiscal Year Ended (a) Currency (a) Less: COVID-19 Constant Currency Segment revenue January 1, 2023 January 2, 2022 Percent Change Constant Currency Impact revenue
Slide 19: Non-GAAP Reconciliations – Adjusted EBITDA
QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 19 Non-GAAP Reconciliations – Adjusted EBITDA Fiscal Quarter Year to date In millions 4Q 2022 4Q 2021 FY 2022 FY 2021 Net income $ 30.3 $ 291.3 $ 548.7 $ 704.2 (a) Pre-combination Ortho net loss — (9.9) (45.9) (54.2) Supplement
Slide 20: quidelortho.com
quidelortho.com